SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

September 01, 2011 07:00 ET

SciClone Pharmaceuticals to Present at Two Investor Conferences in September

Rodman & Renshaw Global Investment Conference: Healthcare Track - Monday, September 12 at 10:50 am ET and China Track - Tuesday, September 13 at 9:35 am ET; UBS Global Life Sciences Conference on Wednesday, September 21 at 8 am ET

FOSTER CITY, CA--(Marketwire - Sep 1, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Global Investment Conference, and UBS Global Life Sciences Conference. SciClone's executives will present a corporate overview and business update at each conference.

Rodman & Renshaw Global Investment Conference
Monday, September 12; 10:50 am ET (Healthcare track)
Tuesday, September 13; 9:35 am ET (China track)
New York City, NY
Presenter: Friedhelm Blobel, PhD, President and CEO

UBS Global Life Sciences Conference
Wednesday, September 21; 8:00 am ET
New York City, NY
Presenter: Gary Titus, Senior Vice President and CFO

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable, China-centric specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the approvals we have in these countries. SciClone markets nearly 20, mostly partnered products in China besides ZADAXIN, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched intervention cardiology product. On the development side, SciClone is evaluating SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi S.A.

Aggrastat is a registered trademark of Merck & Co., Inc.

Contact Information